Trials / Completed
CompletedNCT00248404
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 155 (estimated)
- Sponsor
- Kiadis Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NB1011 |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2007-12-12
- Completion
- 2007-12-12
- First posted
- 2005-11-04
- Last updated
- 2022-05-16
Locations
3 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00248404. Inclusion in this directory is not an endorsement.